A new promising risk stratifying tool based on combination of lymphovascular invasion and systemic immune-inflammation index to predict the survival and to help evaluate the potential benefit of adjuvant chemotherapy for upper tract urothelial carcinoma

MLA

H-C. Jan, et al. “A New Promising Risk Stratifying Tool Based on Combination of Lymphovascular Invasion and Systemic Immune-Inflammation Index to Predict the Survival and to Help Evaluate the Potential Benefit of Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma.” European Urology Open Science, vol. 19, no. e325-, July 2020. EBSCOhost, https://doi.org/10.1016/S2666-1683(20)32773-7.

APA

H-C. Jan, C-Y. Hu, W-H. Yang, & C-H. Ou. (2020). A new promising risk stratifying tool based on combination of lymphovascular invasion and systemic immune-inflammation index to predict the survival and to help evaluate the potential benefit of adjuvant chemotherapy for upper tract urothelial carcinoma. European Urology Open Science, 19(e325-). https://doi.org/10.1016/S2666-1683(20)32773-7

Chicago

H-C. Jan, C-Y. Hu, W-H. Yang, and C-H. Ou. 2020. “A New Promising Risk Stratifying Tool Based on Combination of Lymphovascular Invasion and Systemic Immune-Inflammation Index to Predict the Survival and to Help Evaluate the Potential Benefit of Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma.” European Urology Open Science 19 (e325-). doi:10.1016/S2666-1683(20)32773-7.